Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience.

ABSTRACT:

Background

Interleukin 23 (IL-23) inhibitors, such as guselkumab, risankziumab, and tildrakizumab, have proved to be highly effective and safe for psoriasis treatment either in bio-naïve or bio-experienced patients. A substantial proportion of patients show a primary or secondary inefficacy to IL-17 inhibitors and can benefit from an alternative line of treatment, like IL-23 inhibitors. To date, no sufficient data are available on the effectiveness of IL-23 inhibitors after an anti-IL-17 agent.

Methods

Our study includes 48 patients with moderate to severe psoriasis undergoing a switch from IL-17 to IL-23 inhibitors. This trial is registered with SS_DERMO_20.

Results

The mean PASI (Psoriasis Area Severity Index) decreases from 11.6 to 3.3 at week 16, with responses ma

SUBMITTER: Giordano S 

PROVIDER: S-EPMC10743732 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature